2022.04.12. Innovimmune's first-in-class oral INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors to be presented at the 2022 American Association for Cancer Research Annual Meeting
2643 / 12 - Design and discovery of novel oral INV-88 macrophage migration inhibitory factor (MIF) inhibitors: Potent anti-tumor activity in vitro and in vivo
Anderson Gaweco, MD, PhD, Vincent Chung, MD, Jefferson Tilley, PhD, William Windsor, PhD, Terry Stouch, PhD, John Ellingboe, PhD, Gregg Crichlow, PhD, Philipp Sabanas, MD, Christian Sebesta, MD.
Innovimmune, New York, NY, USA, City of Hope Medical Center, Duarte, CA, USA, Stevens Institute of Technology, Hoboken, NJ, USA, Rudolfinerhaus Privatklinik, Vienna, Austria, Klinik Donaustadt, Vienna, Austria
